Drug Profile
Research programme: small molecule therapeutics - Kareus Therapeutics
Latest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator Kareus Therapeutics
- Class Small molecules
- Mechanism of Action Cannabinoid receptor modulators; Enkephalin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer; Inflammatory pain; Multiple sclerosis; Neuropathic pain
Most Recent Events
- 22 Aug 2023 Discontinued - Preclinical for Alzheimer's disease in Switzerland (unspecified route)
- 22 Aug 2023 Discontinued - Preclinical for Multiple sclerosis in Switzerland (unspecified route)
- 22 Aug 2023 Discontinued for Inflammatory pain in Switzerland (PO)